Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
株価
$0.16328419
時価総額
$204.14K
変化(1日)
4.35%
変化(1年)
102.45%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の利益
Sep 2025 時点の利益 TTM: $-2.06M
Fusion Antibodies plc の最新の財務報告によると、同社の現在の利益は $-2.06M です。2024 年には $-2.89M の利益を上げ、これは 2023 年の利益 $-3.53M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Fusion Antibodies plc の利益の推移(2013 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
同業他社の利益
企業 利益 利益の差
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL